Clinical and economic burden of systemic lupus erythematosus in Colombia

References

• Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol. 2012;24(6):651–657. doi: 10.1016/j.coi.2012.10.004.
   PubMed Web of Science ®Google Scholar
• Tamirou F, Arnaud L, Talarico R, et al. Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open. 2018;4(2):e000793. doi: 10.1136/rmdopen-2018-000793.
   PubMedGoogle Scholar
• Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20(5):453–462. doi: 10.1177/0961203310388445.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955–1959.
   PubMed Web of Science ®Google Scholar
• Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, et al. Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara lupus cohort. Lupus Sci Med. 2022;9(1):e000641. doi: 10.1136/lupus-2021-000641.
   PubMed Web of Science ®Google Scholar
• Valencia P, Mora C, Rossinni Y, et al. Análisis de grupos focales en pacientes colombianos con lupus eritematoso sistémico: una mirada cualitativa a las representaciones de la enfermedad. Rev Colomb Reumatol. 2017;24(1):11–17. doi: 10.1016/j.rcreu.2016.11.001.
   Google Scholar
• Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012;73(7):993–1001. doi: 10.4088/JCP.11r07425.
   PubMed Web of Science ®Google Scholar
• OECD Health at a Glance. 2023 Country note, health at a glance 2023: highlights for Colombia. OECD. https://www.oecd.org › colombia › health-at-a
   Google Scholar
• Castro-Villarreal S, Beltran-Ostos A, Valencia CF. Estimation of prevalence and incremental costs of systemic lupus erythematosus in a middle-income country using machine learning on administrative health data. Value Health Reg Issues. 2021;26:98–104. doi: 10.1016/j.vhri.2021.04.005.
   PubMedGoogle Scholar
• Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356. doi: 10.1136/ard-2022-223035.
   PubMed Web of Science ®Google Scholar
• Díaz-Coronado JC, Rojas-Villarraga A, Hernandez-Parra D, et al. Clinical and sociodemographic factors associated with lupus nephritis in Colombian patients: a cross-sectional study. Reumatol Clin. 2021;17(6):351–356. doi: 10.1016/j.reuma.2019.09.005.
   PubMed Web of Science ®Google Scholar
• Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology. 2020;59(Suppl 5):v4–v11. doi: 10.1093/rheumatology/keaa379.
   PubMedGoogle Scholar
• Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77–95. doi: 10.1016/j.semarthrit.2012.12.002.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology. 2020;59(Suppl 5):v29–v38. doi: 10.1093/rheumatology/keaa382.
   PubMedGoogle Scholar
• Tektonidou MG, Wang Z, Dasgupta A, et al. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res. 2015;67(8):1078–1085. doi: 10.1002/acr.22575.
   Web of Science ®Google Scholar
• Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis. 1986;174(6):357–364. doi: 10.1097/00005053-198606000-00008.
   PubMed Web of Science ®Google Scholar
• Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–323. doi: 10.1097/MAJ.0b013e31827f4ee3.
   PubMed Web of Science ®Google Scholar
• Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009;51(1):66–79. doi: 10.1097/JOM.0b013e31818a405a.
   PubMed Web of Science ®Google Scholar
• Jönsen A, Hjalte F, Willim M, et al. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum. 2016;45(6):684–690. doi: 10.1016/j.semarthrit.2015.11.013.
   PubMed Web of Science ®Google Scholar
• Oglesby A, Korves C, Laliberté F, et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy. 2014;12(2):179–190. doi: 10.1007/s40258-014-0085-x.
   PubMedGoogle Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902–906. doi: 10.1093/rheumatology/keh624.
   PubMed Web of Science ®Google Scholar
• Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, et al. Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012–2016. Lupus. 2019;28(10):1273–1278. doi: 10.1177/0961203319864168.
   PubMed Web of Science ®Google Scholar
• The World Bank. Population ages 15–64, total – Colombia. 2023. https://data.worldbank.org/indicator/SP.POP.1564.TO?locations=CO.
   Google Scholar
• The World Bank. Population ages 65 and above, total – Colombia. 2023. Retrieved from https://data.worldbank.org/indicator/SP.POP.65UP.TO?locations=CO
   Google Scholar
• Nikolopoulos DS, Kostopoulou M, Pieta A, et al. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Sci Med. 2020;7(1):e000394. doi: 10.1136/lupus-2020-000394.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi: 10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi: 10.1177/0272989X12454577.
   PubMed Web of Science ®Google Scholar
• Navarro CE, Betancur JE. Cost-Utility analysis comparing ocrelizumab versus rituximab in the treatment of Relapsing-Remitting multiple sclerosis: the colombian perspective. Value Health Reg Issues. 2023;36:83–91. doi: 10.1016/j.vhri.2023.02.008.
   PubMedGoogle Scholar
• Lasalvia P, Gil-Rojas Y, García Á. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2022;22(6):955–964. doi: 10.1080/14737167.2022.2044310.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li W, Zhang P, et al. Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis—A case-control study. Arthritis Res Ther. 2022;24(1):5. doi: 10.1186/s13075-021-02692-8.
   PubMed Web of Science ®Google Scholar
• Giannouli S, Voulgarelis M, Ziakas PD, et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. 2006;65(2):144–148. doi: 10.1136/ard.2005.041673.
   PubMed Web of Science ®Google Scholar
• Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, et al. Cardiovascular disease in Latin American patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis. 2013;2013:794383–794320. doi: 10.1155/2013/794383.
   PubMedGoogle Scholar
• Anaya JM, Cañas C, Mantilla RD, et al. Lupus nephritis in Colombians: contrasts and comparisons with other populations. Clin Rev Allergy Immunol. 2011;40(3):199–207. doi: 10.1007/s12016-010-8249-4.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432–1441. doi: 10.1002/art.39594.
   PubMed Web of Science ®Google Scholar
• Hammond ER, Desta B, Near AM, et al. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015. Lupus Sci Med. 2021;8(1):e000504. doi: 10.1136/lupus-2021-000504.
   PubMed Web of Science ®Google Scholar
• Ko T, Koelmeyer R, Li N, et al. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Semin Arthritis Rheum. 2022;57:152099. doi: 10.1016/j.semarthrit.2022.152099.
   PubMed Web of Science ®Google Scholar
• The World Bank. Gender Data Portal. 2023. https://genderdata.worldbank.org/countries/colombia/#:∼:text=In%20Colombia%2C%20the%20labor%20force,has%20remained%20roughly%20the%20same
   Google Scholar
• Drenkard C, Bao G, Dennis G, et al. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res. 2014;66(6):878–887. doi: 10.1002/acr.22245.
   Web of Science ®Google Scholar
• Utset TO, Baskaran A, Segal BM, et al. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci Med. 2015;2(1):e000058–e000058. doi: 10.1136/lupus-2014-000058.
   PubMedGoogle Scholar
• The World Bank. GDP per capita (constant LCU) – Colombia. 2023. https://data.worldbank.org/indicator/NY.GDP.PCAP.KN?locations=CO
   Google Scholar
• Moroni G, Frontini G, Ponticelli C. When and how is it possible to stop therapy in patients with lupus nephritis: a narrative review. Clin J Am Soc Nephrol. 2021;16(12):1909–1917. doi: 10.2215/CJN.04830421.
   PubMed Web of Science ®Google Scholar
• Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1(4):163–175. doi: 10.1177/2040622310380100.
   PubMedGoogle Scholar
• Karim MY, Alba P, Cuadrado M-J, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology. 2002;41(8):876–882. doi: 10.1093/rheumatology/41.8.876.
   PubMed Web of Science ®Google Scholar
• Porta S, Danza A, Arias Saavedra M, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):2709. doi: 10.3390/jcm9092709.
   PubMed Web of Science ®Google Scholar
• Kernder A, Richter JG, Fischer-Betz R, et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the LuLa cohort. Lupus. 2021;30(3):431–438. doi: 10.1177/0961203320983445.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Daly RP, Foster SA, et al. The caregiver burden in lupus: findings from UNVEIL, a national online lupus survey in the United States. Lupus. 2017;26(1):54–61. doi: 10.1177/0961203316651743.
   PubMed Web of Science ®Google Scholar
• Fatoye F, Gebrye T, Svenson LW. Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada. PLOS One. 2021;16(5):e0251409. doi: 10.1371/journal.pone.0251409.
   PubMed Web of Science ®Google Scholar
• Panopalis P, Petri M, Manzi S, et al. The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. Arthritis Rheum. 2007;57(1):64–70. doi: 10.1002/art.22470.
   PubMedGoogle Scholar
• Tanaka Y, Mizukami A, Kobayashi A, et al. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study. Int J Rheum Dis. 2018;21(8):1609–1618. doi: 10.1111/1756-185X.13363.
   PubMed Web of Science ®Google Scholar
• Mageau A, Timsit JF, Perrozziello A, et al. The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev. 2019;18(7):733–737. doi: 10.1016/j.autrev.2019.05.011.
   PubMed Web of Science ®Google Scholar
• Prada SI, Pérez AM, Nieto-Aristizábal I, et al. Increase in direct costs for health systems due to lupus nephritis: the case of Colombia. Einstein. 2022;20:eAO6553. doi: 10.31744/einstein_journal/2022AO6553.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Wilson K, Ogelsby A, et al. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med. 2013;55(11):1262–1270. doi: 10.1097/JOM.0000000000000008.
   PubMed Web of Science ®Google Scholar
• Jönsen A, Bengtsson AA, Hjalte F, et al. Total cost and cost predictors in systemic lupus erythematosus – 8-years follow-up of a Swedish inception cohort. Lupus. 2015;24(12):1248–1256. doi: 10.1177/0961203315584812.
   PubMed Web of Science ®Google Scholar
• Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25(7):727–734. doi: 10.1177/0961203315627202.
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Novack V. Mortality and multiple causes of death in systemic lupus erythematosus – role of the death certificate. J Rheumatol. 2012;39(3):458–460. doi: 10.3899/jrheum.111556.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76(12):2009–2016. doi: 10.1136/annrheumdis-2017-211663.
   PubMed Web of Science ®Google Scholar